Purpose: The modalities for anti-dementia drugs' discontinuation are not consensual.
Objective: The objectives of the study were the followings, describe: i) the reasons for discontinuation of anti-dementia drugs of patients treated in a residency for dependent elderly people, ii) security of sudden discontinuation, iii) evolution of troubles.
Methods: Our longitudinal descriptive pilot study aimed at observing consequences of the sudden discontinuation of anti-dementia drugs in a population with a moderate to severe stage of Alzheimer's disease. The study took place in a French residency for dependent elderly people, treated with at least one of the following treatments: rivastigmine, donepezil, galantamine and/or memantine. Based on multidisciplinary decision, as recommended, patient's anti-dementia treatment have been stopped or not. Criteria have been collected for 6 months and compared between the two groups: safety, motivation for discontinuation, score mini-mental state examination (MMSE), psycho-behavior criteria and finally the concomitant prescription of psychotropic drugs.
Results: Thirty-three patients were included: the revaluation of anti-dementia treatment led to 22 discontinuations and 11 continuations. Motivations to stop antidementia treatment were: too advanced dementia (48%), lack of therapeutic benefit (28%) or too much of psychotropic medications (24%). The sudden discontinuation was well tolerated with no withdrawal syndrome observed. The variation of MMSE at 6 months was -1.8 (SD 2.2) in the discontinuation group (n = 14) versus -2.2 (SD 2.0) in the continuation group (n = 6). The psycho-behavior disorders have not been aggravated. A reduction in number of psychotropic drugs in the discontinuation group was observed.
Conclusion: In this pilot study, the revaluation in accordance with the recommendations of the Haute autorité de santé (HAS) led to the discontinuation of two third of anti-dementia drugs. Safety of sudden discontinuation of MSD remains to be studied.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2515/therapie/2014217 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The impact of genetic variability on Alzheimer's therapies: obstacles for pharmacogenetic progress.
Expert Opin Drug Metab Toxicol
January 2025
EuroEspes Biomedical Research Center, International Center of Neuroscience and Genomic Medicine, Bergondo, Corunna, Spain.
Introduction: Genetic load influences the therapeutic response to conventional drugs in Alzheimer's disease (AD). Pharmacogenetics (PGx) is the best option to reduce drug-drug interactions and adverse drug reactions in patients undergoing polypharmacy regimens. However, there are important limitations that make it difficult to incorporate pharmacogenetics into routine clinical practice.
View Article and Find Full Text PDFBrain aging rejuvenation factors in adults with genetic and sporadic neurodegenerative disease.
Brain Commun
January 2025
Department of Neurology, Memory and Aging Center, University of California, San Francisco, CA 94158, USA.
The largest risk factor for dementia is age. Heterochronic blood exchange studies have uncovered age-related blood factors that demonstrate 'pro-aging' or 'pro-youthful' effects on the mouse brain. The clinical relevance and combined effects of these factors for humans is unclear.
View Article and Find Full Text PDFPharmacodynamic and Clinical Effects of Ginkgo Biloba Extract EGb 761 and Its Phytochemical Components in Alzheimer's Disease.
J Alzheimers Dis
October 2024
Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain.
Article Synopsis
- Plant extracts are complex mixtures, and this complexity challenges scientists in pharmacological and clinical research, particularly with ginkgo biloba leaf extract.
- A narrative review highlights ginkgo biloba's composition and clinical evidence for treating Alzheimer's disease, noting its approval as a medicinal product in various regions.
- While ginkgo biloba extract EGb 761 is well-researched and shows promise against cognitive decline, its exact mechanism of action remains unclear, and clinical study results vary.
How much risk does delirium represent for the development of dementia?: Retrospective cohort study from over 260,000 patients record in a solitary institution.
Front Psychiatry
September 2024
Department of Neuropsychiatry, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Article Synopsis
- Delirium is a problem that often affects older people in hospitals, and it might increase the chances of them getting dementia later on.
- A study looked at over 261,000 patients in Osaka to see how delirium during hospital stays is related to the development of dementia.
- The results showed that people who experienced delirium had dementia show up much faster compared to those who didn't, highlighting the need to prevent delirium and watch for cognitive decline in these patients.
Better cardiovascular health is associated with slowed clinical progression in autosomal dominant frontotemporal lobar degeneration variant carriers.
Alzheimers Dement
October 2024
Department of Neurology, University of California, San Francisco, Memory and Aging Center, San Francisco, California, USA.
Article Synopsis
- - Cardiovascular health, evaluated through Life's Simple 7 (LS7), is linked to slower cognitive decline and better brain integrity in patients with autosomal dominant frontotemporal lobar degeneration (FTLD).
- - A study involving 247 FTLD genetic variant carriers and 189 non-carrier controls found that those with better cardiovascular health had slower memory and language declines, as well as less accumulation of frontal white matter hyperintensities (WMHs).
- - Maintaining good cardiovascular health could be a key modifiable strategy to improve cognitive outcomes and brain health in individuals at risk for genetic forms of dementia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!